<DOC>
	<DOCNO>NCT01137916</DOCNO>
	<brief_summary>The objective present study evaluate activity safety imatinib patient aggressive fibromatosis , receive standard therapy , show inoperable recurrent tumor disease readily controllable surgery radiotherapy .</brief_summary>
	<brief_title>Study Evaluate Imatinib Desmoid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Fibroma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients histological confirm aggressive fibromatosis ( desmoid tumor ) Measurable disease accord RECIST criterion Evidence relapse disease progression within last 6 month ( base RECIST criterion ) compute tomography magnetic resonance image No possibility complete surgical resection case surgical therapy leave large tissue defect , functional deficit disfigurement would require No possibility curative radiotherapy acceptable toxicity and/or late morbidity Previous treatment tumor region surgical intervention and/or radiotherapy and/or antihormonal therapy possible Age &gt; = 18 year WHO PS &lt; = 1 Effective contraception study medication Signed informed consent form Surgical intervention &lt; 4 week Prior therapy imatinib Pregnancy lactation Severe hepatic dysfunction Known allergic reaction imatinib one components The following laboratory value : Absolute neutrophil count &lt; 1.5 x 103/mm3 , Platelets &lt; 100,000/mm3 , Serum creatinine &gt; = 2.5 mg/dl , SGOT and/or SGPT &gt; 2.5 x ULN ( upper limit normal ) , Total bilirubin &gt; 1.5 x ULN Participation another study ( four week study ) Prior malignancy apart completely resect basal cell carcinoma skin carcinoma situ uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>